Abstract
In this work, we have developed an ESIPT-based benzimidazole platform (MO-E1 and MO-E2) for the two-photon cell imaging of ONOO- and a potential ONOO--activated theranostic scaffold (MO-E3). Each benzimidazole platform, MO-E1-3, were shown to rapidly detect ONOO- at micromolar concentrations (LoD = 0.28 μM, 6.53 μM and 0.81 μM respectively). The potential theranostic MO-E3 was shown to release the parent fluorophore and drug indomethacin in the presence of ONOO- but unfortunately did not perform well in vitro due to low solubility. Despite this, the parent scaffold MO-E2 demonstrated its effectiveness as a two-photon imaging tool for the ratiometric detection of endogenous ONOO- in RAW264.7 macrophages and rat hippocampus tissue. These results demonstrate the utility of this ESIPT benzimidazole-based platform for theranostic development and bioimaging applications.
Highlights
Fluorescent probes using bespoke chemical architectures are rationally designed to elicit a uorescent response a er reacting with a target molecule
Probe 3 was targeted to the endoplasmic reticulum (ER).[5,12]
Following a different mechanism of activation, probe 4 designed by Li et al was used for visualisation of ONOOÀ in neurovascular ischemia progression in the brain of a live mouse.[13]
Summary
Fluorescent probes using bespoke chemical architectures are rationally designed to elicit a uorescent response a er reacting with a target molecule. A fluorescent ESIPT-based benzimidazole platform for the ratiometric two-photon imaging of ONOOÀ in vitro and ex vivo† We have developed an ESIPT-based benzimidazole platform (MO-E1 and MO-E2) for the twophoton cell imaging of ONOOÀ and a potential ONOOÀ-activated theranostic scaffold (MO-E3).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
